Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.
Amer M ZeidanJan Philipp BewersdorfVanessa HasleRory Michael ShallisEthan ThompsonDaniel Lopes de MenezesShelonidta RoseIsaac BossStephanie HaleneTorsten HaferlachBrian A FoxPublished in: Therapeutic advances in hematology (2024)
FUSION trial (NCT02775903).